News and Events

Replimune Announces First Patients Dosed In A Phase 1/2 Clinical Trial Of Its RP1 Oncolytic Immunotherapy In Patients With Advanced Solid Tumors

– Woburn, MA, November 14, 2017

Developing the
‘on’ switch for
immuno-oncology

Cancer is one of the most difficult diseases to treat. It is constantly changing, requiring new and more sophisticated therapies.

Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response.

Oncolytic immunotherapy enhances the effectiveness of immune checkpoint blockade and is expected to become the second cornerstone of immuno-oncology (IO) approaches, moving beyond incremental improvements in cancer treatment to help more patients overcome their disease.

Our Immulytic™ Platform

The “On-Switch” for
Immuno-Oncology

Novel Therapeutics

Rapidly Advancing
Clinical Programs

Experienced Team

Pioneers in Oncolytic
Immunotherapy